



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

REC'D 26 NOV 2004

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03024865.2

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Anmeldung Nr:
Application no.: 03024865.2
Demande no:

Anmeldetag:
Date of filing: 31.10.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Lonza AG
Muncheinsteinerstrasse 38
4052 Basel
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Process for the preparation of (S)- or (S)-4-halo-3-hydroxybutyrates

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07C67/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:


AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

1

Description

The invention relates to a process for the preparation of enantiomerically pure (S)- or (R)-4-halo-3-hydroxybutyrates of formula

5



wherein R^1 is CH_2X , CHX_2 or CX_3 and X independently represents Cl and/or Br and wherein R^2 is C_{1-6} -alkyl, C_{3-8} -cycloalkyl, aryl or aralkyl by asymmetric hydrogenation of

10

4-halo-3-oxobutyrate of formula



wherein R^1 , R^2 and X are as defined above.

15

Here and hereinbelow the term "enantiomerically pure compound" comprises optically active compounds with an enantiomeric excess (ee) of at least 90 %.

20

Here and hereinbelow the term " C_{1-6} -alkyl" represents a linear or branched alkyl group having 1 to 6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl and hexyl, which can be optionally further substituted by one or more halogen atoms.

25

Here and hereinbelow the term " C_{1-4} -alkoxy" represents a linear or branched alkoxy group having 1 to 6 carbon atoms, for example methoxy, ethoxy, propyloxy, isopropyloxy, *n*-butyloxy, isobutyloxy, *sec*-butyloxy, *tert*-butyloxy, which can be optionally further substituted by one or more halogen atoms.

30

Here and hereinbelow the term " C_{3-8} -cycloalkyl" represents a cycloaliphatic group having 3 to 8 carbon atoms, i.e. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

Here and hereinbelow the term "aryl" represents an aromatic group, preferably phenyl or

naphthyl, which is, optionally substituted with one or more halogen atoms, C₁₋₄-alkyl and/or C₁₋₄-alkoxy, wherein the alkyl and alkoxy substituents optionally are further substituted with one or more halogen atoms.

- 5 Here and hereinbelow the term "aralkyl" represents a linear C₁₋₄-alkyl moiety optionally further substituted by halogen atoms, which is connected to an optionally further substituted aryl moiety as defined above.

- 10 Generally 3-hydroxybutyrates and derivatives thereof are useful key intermediates in preparative industrial chemistry. Among the derivatives especially ethyl (S)-4-chloro-3-hydroxybutyrate is an important building block for the preparation of HMG-CoA reductase inhibitors like Rosuvastatin[®] or Atorvastatin[®]. To provide said hydroxybutyrates in pharmaceutically acceptable qualities and to avoid costly separation of the enantiomers the processes for asymmetric hydrogenation should result in high ee, preferably in the
15 range of 90 to 100 %.

Asymmetric hydrogenation is mostly carried out with chiral transition metal-ligand complexes, wherein the transition metal is ruthenium or rhodium and wherein the ligands are often substituted chiral bidentate diphosphines.

20

WO-A-02/40492 discloses asymmetric hydrogenation of ethyl 4-chloro-3-oxobutyrate using a catalyst containing a (S)-6-methoxy-5,6'-benzo-2,2'-bis(diphenylphosphino)-biphenyl ligand. The (S)-product is obtained with an ee of 83%.

- 25 A new class of methylenedioxy and ethylenedioxy substituted diphosphine ligands and their use for the asymmetric hydrogenation of methyl 2-benzamidomethyl-3-oxobutyrate has been described in EP-A-0 850 945. Pai, C.-C. et al, *Tetrahedron Lett.* 2002, 43, 2789-2792 discloses the use of said ligands for the asymmetric hydrogenation of ethyl 4-chloro-3-oxobutyrate.


30

EP-A-0 955 303 describes the asymmetric hydrogenation of 4-methylene-2-oxetanone (diketene) to 4-methyl-2-oxetanone, a β -lactone of 3-hydroxybutyric acid using ruthenium iodo derivatives of the ligands disclosed in EP-A-0 850 945.

The technical problem to be solved by the present invention was to provide an alternative general process for the asymmetric hydrogenation of 4-halo-3-oxobutyrate to yield enantiomerically pure (*S*)- or (*R*)-4-halo-3-hydroxybutyrate.


The problem could be solved according to the process of claim 1.

The invention provides a process for the preparation of enantiomerically pure (*S*)- or (*R*)-4-halo-3-hydroxybutyric acid esters of formula




wherein R^1 is CH_2X , CHX_2 or CX_3 and X independently represents Cl and/or Br and wherein R^2 is C_{1-6} -alkyl, C_{3-8} -cycloalkyl, aryl or aralkyl, each aryl or aralkyl being

optionally further substituted with one or more C_{1-4} -alkyl groups and/or halogen atoms, by asymmetric hydrogenation of 4-halo-3-oxobutyric acid esters of formula



wherein R^1 , R^2 and X are as defined above

in the presence of a catalyst of a ruthenium complex comprising a chiral ligand of formula



In a preferred embodiment R^1 is CH_2X and X represents Cl or Br, more preferably R^1 is CH_2X and X represents Cl.

WO 03/029259 discloses a process for the asymmetric hydrogenation of alkyl and aryl derivatives of 3-oxoacid esters using a ruthenium complex of the ligand of formula III.

Several examples for asymmetric hydrogenation of esters of fluorinated 3-oxoacids are presented, but hydrogenations of compounds of formula II are not disclosed. All fluorinated aliphatic 3-hydroxyacid esters disclosed therein, like ethyl 4,4,4-trifluoro-3-hydroxybutyrate, are obtainable only at moderate ee-levels in the range of 70 to 80%.

5

Regarding EP-A-0 850 945 in the light of the experimental results of WO 03/029259 it seemed very unlikely that transition metal complexes of 5,5'-bis(diphenylphosphanyl)-2,2,2',2'-tetrafluoro-4,4'-bi[benzo-1,3-dioxolyl] ligands of formula III (Fluoxphos) would be suitable for the asymmetric hydrogenation of compounds of formula II.

10

Surprisingly the asymmetric hydrogenation of 4-chloro-3-oxobutyrate and 4,4,4-trichloro-3-oxobutyrate using ruthenium complexes containing the ligand of formula III ((-)-Fluoxphos and (+)-Fluoxphos) gives very high ee-levels.

15

In a preferred embodiment R^2 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, *n*-butyl and *tert*-butyl. More preferred R^2 is methyl, ethyl or isopropyl. Particularly preferred R^2 is methyl or ethyl.

In another preferred embodiment R^2 is, optionally substituted, phenyl or naphthyl.

20

The hydrogenation is carried out with a catalyst solution in a polar solvent like C_{1-4} -alcohols, dimethylsulfoxide (DMSO), dimethylformamide (DMF), acetonitrile (MeCN) or mixtures thereof. Preferably the polar solvent is methanol, ethanol or isopropyl alcohol or a mixture thereof. The solution may contain further solvent additives like dichloromethane.

25

The catalyst solution can be prepared in situ by dissolving a ruthenium salt $Ru^{n+}Y_n^-$, wherein *n* is 2 or 3 and wherein Y^- is Cl^- , Br^- , I^- , BF_4^- , AsF_6^- , SbF_6^- , PF_6^- , ClO_4^- or OTf^- (trifluoromethane sulfonate or triflate) or another suitable counterion in a polar solvent and mixing with a suitable amount of the ligand of formula III, optionally further mixed with at least one stabilizing ligand.

30

Alternatively, the catalyst solution can be obtained by mixing a catalyst precursor complex,

i.e. a preformed ruthenium complex which already contains at least one stabilizing ligand, in a polar solvent with a suitable amount of further ligands. The catalyst precursor complex comprises at least one stabilizing ligand such as a diene, alkene or arene. In a preferred embodiment the stabilizing ligand is 1,5-cyclooctadiene (cod), norbornadiene (nbd) or *p*-cymene (cym). Particularly preferred the stabilizing ligand is *p*-cymene.

In a further preferred embodiment the catalyst precursor complex comprises at least one chiral ligand of formula III (Fluoxphos).

In a further particularly preferred embodiment the catalyst precursor complex comprises at least one polar solvent molecule as stabilizing ligand, such as dimethylsulfoxide (DMSO), dimethylformamide (DMF) or acetonitrile (MeCN).

Examples for catalyst precursor complexes containing such stabilizing ligands are $[\text{Ru}_2\text{Cl}_4(\text{cym})_2]$, $[\text{Ru}_2\text{Br}_4(\text{cym})_2]$, $[\text{RuCl}(\text{Fluoxphos})(\text{benzene})]\text{Cl}$, $[\text{RuCl}_2(\text{Fluoxphos})\cdot\text{DMF}]$, $[\text{RuCl}_2(\text{Fluoxphos})\cdot\text{DMSO}]$ and $[\text{Ru}_2\text{Cl}_4(\text{cod})_2\cdot\text{MeCN}]$.

Furthermore, the catalyst solution can be obtained by dissolving a preformed chiral ruthenium complex which already contains all required ligands.

Several examples for general applicable methods for the preparations of catalysts and catalyst solutions are disclosed in Ashworth, T. V. et al. *S. Afr. J. Chem.* 1987, 40, 183-188, WO 00/29370 and Mashima, K. *J. Org. Chem.* 1994, 59, 3064-3076.

In a preferred embodiment the catalyst precursor complex is prepared by mixing bis[(1-isopropyl-4-methylbenzene)dichloro ruthenium] of the formula $[\text{Ru}_2\text{Cl}_4(\text{cym})_2]$ with either the (-)-Fluoxphos or the (+)-Fluoxphos ligand in a polar solvent.

Preferably the metal salt $\text{Ru}^{n+}\text{Y}_n^-$, or the ruthenium complex is mixed with the chiral bidentate phosphine at a ratio of 1:5 to 5:1. More preferably the Ru/phosphine ratio is in the range of 1:2 to 2:1. Most preferably the Ru/phosphine ratio is 1:1.

In a particular embodiment the counterion of the transition metal salt, the catalytic precursor complex and the ruthenium complex of the ligand of formula III is Cl^- , Br^- , I^- , BF_4^- , AsF_6^- , SbF_6^- , PF_6^- , ClO_4^- or OTf^- , more preferably Cl^- , I^- or BF_4^- .

In a preferred embodiment the hydrogen pressure during the reaction is in the range of 1 to 60 bar and more particularly preferred in the range of 2 to 35 bar.

The hydrogenation can be carried out at a temperature in the range of 20 to 150 °C.

- 5 Preferably the temperature is in the range of 70 to 130 °C. Particularly preferred the temperature is in the range of 80 to 120 °C.

The present invention is illustrated by the following non-limiting examples.

10 **Examples:**

Example 1:

Ethyl (S)-4-chloro-3-hydroxybutyrate (Formula (S)-I, $R^1 = CH_2Cl$, $R^2 = ethyl$):

In a 150 mL autoclave under argon atmosphere $RuCl_3$ (10.2 mg, 0.049 mmol),

- 15 (–)-5,5'-bis(diphenylphosphanyl)-2,2',2'-tetrafluoro-4,4'-bi[benzo-1,3-dioxolyl]
(i.e. (–)-Fluoxphos) (34.2 mg, 0.050 mmol) and ethyl 4-chloro-3-oxobutyrate (0.81 g,
4.9 mmol, approx. 98.5%) is dissolved in degassed ethanol (30 mL). After flushing the
autoclave with argon hydrogenation is carried out during 2 hours at 80 °C and at 4 bar
hydrogen pressure. After cooling to room temperature the reaction solution is directly
20 analyzed by GC for conversion (column: HP-101 25 m / 0.2 mm) and enantiomeric excess
(ee) (column: Lipodex-E 25 m / 0.25 mm). Conversion is 100% at an ee of 97.6%.

Example 2:

Ethyl (S)-4-chloro-3-hydroxybutyrate (Formula (S)-I, $R^1 = CH_2Cl$, $R^2 = ethyl$):

- 25 In a 250 mL autoclave in an argon atmosphere bis[(1-isopropyl-4-methylbenzene)dichloro
ruthenium] (i.e. $[Ru_2Cl_4(cym)_2]$) (6.7 mg, 0.011 mmol), (–)-Fluoxphos (16.0 mg,
0.023 mmol) and ethyl 4-chloro-3-oxobutyrate (9.11 g, 54.5 mmol, approx. 98.5%) is
dissolved in degassed ethanol (30 mL). After flushing the autoclave with argon
hydrogenation is carried out during 2.3 hours at 90 °C and at 30 bar hydrogen pressure.
30 After cooling to room temperature the reaction solution is directly analyzed by GC for
conversion (column: HP-101 25 m / 0.2 mm) and ee (column: Lipodex-E 25 m / 0.25 mm).
Conversion is 100% at an ee of 95.8%.

Example 3:

Ethyl (*R*)-4-chloro-3-hydroxybutyrate (Formula (*R*)-I, $R^1 = \text{CH}_2\text{Cl}$, $R^2 = \text{ethyl}$):

In a 1 L autoclave under argon atmosphere RuCl_3 (10.0 mg, 0.048 mmol), (+)-Fluoxphos (36.1 mg, 0.053 mmol) and ethyl 4-chloro-3-oxobutyrate (8.0 g, 48 mmol, approx. 98.5%) is dissolved in degassed ethanol (170 mL) and dichloromethane (40 mL). After flushing the autoclave with argon hydrogenation is carried out during 90 minutes at 82 °C and at 35 bar hydrogen pressure. After cooling to room temperature the reaction solution is directly analyzed by GC for conversion (column: HP-101 25 m / 0.2 mm) and ee (column: Lipodex-E 25 m / 0.25 mm). Conversion is 100% at an ee of 97.8%.

Example 4:

Ethyl (*R*)-4-chloro-3-hydroxybutyrate (Formula (*R*)-I, $R^1 = \text{CH}_2\text{Cl}$, $R^2 = \text{ethyl}$):

In a 1 L autoclave under argon atmosphere $[\text{Ru}_2\text{Cl}_4(\text{cod})_2 \cdot \text{MeCN}]$ (15.8 mg, 0.026 mmol, prepared from RuCl_3 and 1,5-cyclooctadiene as disclosed in Ashworth, T. V. et al. *S. Afr. J. Chem.* 1987, 40, 183-188, (+)-Fluoxphos (36.1 mg, 0.053 mmol) and ethyl 4-chloro-3-oxobutyrate (8.0 g, 48 mmol, approx. 98.5%) is dissolved in degassed ethanol (170 mL) and dichloromethane (40 mL). After flushing the autoclave with argon hydrogenation is carried out during 80 minutes at 82 °C and at 35 bar hydrogen pressure. After cooling to room temperature the reaction solution is directly analyzed by GC for conversion (column: HP-101 25 m / 0.2 mm) and ee (column: Lipodex-E 25 m / 0.25 mm). Conversion is 100% at an ee of 97.3%.

Example 5:

Ethyl (*S*)-4-chloro-3-hydroxybutyrate (Formula (*S*)-I, $R^1 = \text{CH}_2\text{Cl}$, $R^2 = \text{ethyl}$):

In a 1 L autoclave under argon atmosphere $[\text{Ru}_2\text{Cl}_4(\text{cym})_2]$ (5.0 mg, 0.008 mmol, (-)-Fluoxphos (12.1 mg, 0.018 mmol) and ethyl 4-chloro-3-oxobutyrate (27.0 g, 162 mmol, approx. 98.5%) is dissolved in degassed ethanol (340 mL) and dichloromethane (80 mL). After flushing the autoclave with argon hydrogenation is carried out during 70 minutes at 110 °C and at 22 bar hydrogen pressure. After cooling to room temperature the reaction solution is directly analyzed by GC for conversion (column: HP-101 25 m / 0.2 mm) and ee (column: Lipodex-E 25 m / 0.25 mm). Conversion is 100% at an ee of 98.1%.

Example 6:

Ethyl (*S*)-4-chloro-3-hydroxybutyrate (Formula (*S*)-I, $R^1 = \text{CH}_2\text{Cl}$, $R^2 = \text{ethyl}$):

- In a 1 L autoclave under argon atmosphere $[\text{RuI}((-)\text{-Fluoxphos})(\text{cym})]\text{I}$ (35 mg, 0.030 mmol, prepared from $(-)\text{-Fluoxphos}$ and $[\text{Ru}_2\text{I}_4(\text{cym})_2]$ as disclosed in
- 5 WO 00/29370, and ethyl 4-chloro-3-oxobutyrate (33.4 g, 200 mmol, approx. 98.5%) is dissolved in degassed ethanol (340 mL) and dichloromethane (80 mL). After flushing the autoclave with argon hydrogenation is carried out during 170 minutes at 100 °C and at 22 bar hydrogen pressure. After cooling to room temperature the reaction solution is directly analyzed by GC for conversion (column: HP-101 25 m / 0.2 mm) and ee (column:
- 10 Lipodex-E 25 m / 0.25 mm). Conversion is 100% at an ee of 97.4%.

Example 7:

Ethyl (*S*)-4-chloro-3-hydroxybutyrate (Formula (*S*)-I, $R^1 = \text{CH}_2\text{Cl}$, $R^2 = \text{ethyl}$):

- In a 1 L autoclave under argon atmosphere $[\text{RuCl}((-)\text{-Fluoxphos})(\text{cym})]\text{BF}_4$ (23 mg, 0.022 mmol, prepared from $(-)\text{-Fluoxphos}$ and $[\text{Ru}_2\text{Cl}_4(\text{cym})_2]$ and AgBF_4 as disclosed in
- 15 Mashima, K., *J. Org. Chem.* 1994, 59, 3064-3076, and ethyl 4-chloro-3-oxobutyrate (33.4 g, 200 mmol, approx. 98.5%) is dissolved in degassed ethanol (340 mL) and dichloromethane (80 mL). After flushing the autoclave with argon hydrogenation is carried out during 180 minutes at 100 °C and at 22 bar hydrogen pressure. After cooling to room
- 20 temperature the reaction solution is directly analyzed by GC for conversion (column: HP-101 25 m / 0.2 mm) and ee (column: Lipodex-E 25 m / 0.25 mm). Conversion is 100% at an ee of 98.0%.

Example 8:

- 25 *tert*-Butyl 4-chloro-3-hydroxybutyrate (Formula I, $R^1 = \text{CH}_2\text{Cl}$, $R^2 = \text{tert-butyl}$):
- In a 150 mL autoclave under argon atmosphere $[\text{Ru}_2\text{Cl}_4(\text{cym})_2]$ (7.7 mg, 0.013 mmol), $(+)\text{-Fluoxphos}$ (17.9 mg, 0.026 mmol) and *tert*-butyl 4-chloro-3-oxobutyrate (assay 96.9% by GC, 1.0 g, 5.2 mmol) is dissolved in degassed ethanol (30 mL). After flushing the autoclave with argon hydrogenation is carried out during 4 hours at 80 °C and at 4 bar
- 30 hydrogen pressure. After cooling to room temperature the reaction solution is directly analyzed by GC for conversion (column: HP-101 25 m / 0.2 mm). Analysis for
- enantiomeric excess is performed by $^1\text{H-NMR}$ using europium(III) tris[3-(trifluoromethyl-

hydroxymethylene)-(+) -camphorate] as shift reagent and CDCl_3 as solvent. Conversion is >99%. Yield is approx. 67% at an ee of one enantiomer of 93.2%.

Example 9:

- 5 Ethyl 4,4,4-trichloro-3-hydroxybutyrate (Formula I, $\text{R}^1 = \text{CCl}_3$, $\text{R}^2 = \text{ethyl}$):
In a 150 mL autoclave under argon atmosphere $[\text{Ru}_2\text{Cl}_4(\text{cym})_2]$ (7.6 mg, 0.012 mmol),
(+) -Fluoxphos (17.8 mg, 0.026 mmol) and ethyl 4,4,4-trichloro-3-oxobutyrate (assay 97%,
1.21 g, 5.2 mmol) is dissolved in degassed ethanol (30 mL). After flushing the autoclave
with argon hydrogenation is carried out during 7.5 hours at 80 °C and at 4 bar hydrogen
10 pressure. After cooling to room temperature the reaction solution is directly analyzed by
GC for conversion (column: HP-101 25 m / 0.2 mm). Conversion is 99% at an ee of one
enantiomer of 95.3%. Analysis for enantiomeric excess is performed by ^1H -NMR using
europium(III) tris[3-(trifluoromethylhydroxymethylene)-(+) -camphorate] as shift reagent
and CDCl_3 as solvent.


15

Comparative Example 1:

- Ethyl (*S*)-4-chloro-3-hydroxybutyrate (Formula (*S*)-I, $\text{R}^1 = \text{CH}_2\text{Cl}$, $\text{R}^2 = \text{ethyl}$):
In a 250 mL autoclave in an argon atmosphere $[\text{Ru}_2\text{Cl}_4(\text{cym})_2]$ (6.7 mg, 0.011 mmol),
(-) -5,5'-bis(diphenylphosphanyl)-4,4'-bi[benzo-1,3-dioxolyl] (14.3 mg, 0.023 mmol) and
20 ethyl 4-chloro-3-oxobutyrate (9.10 g, 54.5 mmol, approx. 98.5%) is dissolved in degassed
ethanol (30 mL). After flushing the autoclave with argon hydrogenation is carried out
during 2.3 hours at 90 °C and at 30 bar hydrogen pressure. After cooling to room
temperature the reaction solution is directly analyzed by GC for conversion (column:
HP-101 25 m / 0.2 mm) and ee (column: Lipodex-E 25 m / 0.25 mm). Conversion is 100%
25 at an ee of 89.5%.

Claims

1. Process for the preparation of enantiomerically pure (*S*)- or (*R*)-4-halo-3-hydroxybutyrate of formula




wherein R^1 is CH_2X , CHX_2 or CX_3 and X independently represents Cl and/or Br and wherein R^2 is C_{1-6} -alkyl, C_{3-6} -cycloalkyl, aryl or aralkyl, each aryl or aralkyl being optionally further substituted with one or more C_{1-4} -alkyl groups and/or halogen atoms,

which process comprises the asymmetric hydrogenation of 4-halo-3-oxobutyrate of formula



wherein R^1 , R^2 and X are as defined above

in the presence of a catalyst of a ruthenium complex comprising a chiral ligand of formula




2. The process of claim 1, wherein the ruthenium complex comprising a ligand of formula III comprises at least one diene, alkene or arene or polar solvent molecule as stabilizing ligand.
3. The process of claim 1 or 2, wherein the ruthenium complex comprising a ligand of formula III comprises at least one molecule of 1,5-cyclooctadiene or *p*-cymene as stabilizing ligand.

4. The process of one of claims 1 to 3, wherein the hydrogenation is carried out in a solution comprising a polar solvent selected from the group consisting of C₁₋₄-alcohols, dimethylsulfoxide, dimethylformamide, acetonitrile and mixtures thereof, wherein the solvent optionally contains further solvent additives.
5. The process of any one of claims 1 to 4, wherein the counterion of the ruthenium complex is selected from the group consisting of Cl⁻, Br⁻, I⁻, BF₄⁻, AsF₆⁻, SbF₆⁻, PF₆⁻, ClO₄⁻ and OTf⁻.
6. The process of any one of claims 1 to 5, wherein the ruthenium complex is prepared by mixing the complex of formula [Ru₂Cl₄(cym)₂] with the Fluoxphos ligand in a polar solvent.
7. The process of any of claims 1 to 6, wherein the hydrogen pressure during the reaction is in the range of 1 to 60 bar and preferably in the range of 2 to 35 bar.

Abstract

Process for the preparation of enantiomerically pure (*S*)- or (*R*)-4-halo-3-hydroxybutyrates of formula

5




wherein R^1 is CH_2X , CHX_2 or CX_3 and X independently represents Cl and/or Br and
wherein R^2 is C_{1-6} -alkyl, C_{3-8} -cycloalkyl, aryl or aralkyl, each aryl or aralkyl being
10 optionally further substituted with one or more C_{1-4} -alkyl groups and/or halogen atoms, by
asymmetric hydrogenation of 4-halo-3-oxobutyric acid esters of formula



15 wherein R^1 , R^2 and X are as defined above
in the presence of a catalyst of a ruthenium complex comprising a chiral ligand of the
formula

20



III.

25

30

Basel, October 30, 2003

Dr. B. Gallasch

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.